IRIS

Compelling experimental evidences point to monitoring of the absolute number of circulating ICOS-positive T cells as an early predictive marker of clinical activity of anti-CTLA-4 antibodies in cancer patients. Here, we report available data focusing on this issue and operative procedures to detect ICOS expression on circulating peripheral blood mononuclear cells during CTLA-4 blockade therapy.

Danielli, R., Cutaia, O., Fazio, C., Bertocci, E., Fonsatti, E., Maio, M., et al. (2016). ICOS expression as immunologic marker in immune activating monoclonal antibodies. In A. Bondanza, M. Casucci (a cura di), Tumor Immunology - Methods and Protocols (pp. 133-139). New York : Humana Press [10.1007/978-1-4939-3338-9_13].

ICOS expression as immunologic marker in immune activating monoclonal antibodies

Danielli, R.
;Cutaia, O.;Fazio, C.;Bertocci, E.;Maio, M.;
2016-01-01

Abstract

Compelling experimental evidences point to monitoring of the absolute number of circulating ICOS-positive T cells as an early predictive marker of clinical activity of anti-CTLA-4 antibodies in cancer patients. Here, we report available data focusing on this issue and operative procedures to detect ICOS expression on circulating peripheral blood mononuclear cells during CTLA-4 blockade therapy.
2016
978-1-4939-3336-5
978-1-4939-3338-9
Danielli, R., Cutaia, O., Fazio, C., Bertocci, E., Fonsatti, E., Maio, M., et al. (2016). ICOS expression as immunologic marker in immune activating monoclonal antibodies. In A. Bondanza, M. Casucci (a cura di), Tumor Immunology - Methods and Protocols (pp. 133-139). New York : Humana Press [10.1007/978-1-4939-3338-9_13].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11365/1093044